Fgfr3 Mutation | List of Frontiers open access articles

Case Report

Published on 12 Apr 2021

Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report

in Genitourinary Oncology

Pietro Parcesepe
Luigi Coppola
Andrea Remo
Mario Rosario D’Andrea
Giulia Coppola
Michele Simbolo
Erminia Manfrin
Aldo Scarpa
Elena De Santis
Guido Giordano

Frontiers in Oncology

doi 10.3389/fonc.2021.663489

6,341 views
6 citations

Case Report

Published on 24 May 2021

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

in Genitourinary Oncology

Jian-zhou Cao
Wei Wu
Jin-feng Pan
Hong-wei Wang
Jun-hui Jiang
Qi Ma

Frontiers in Oncology

doi 10.3389/fonc.2021.643413

4,867 views
8 citations

Original Research

Published on 20 Aug 2021

A Novel Ferroptosis-Related Prognostic Signature Reveals Macrophage Infiltration and EMT Status in Bladder Cancer

in Cell Death and Survival

Yilin Yan
Jinming Cai
Zhengnan Huang
Xiangqian Cao
Pengfei Tang
Zeyi Wang
Fang Zhang
Shujie Xia
Bing Shen

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.712230

11,046 views
30 citations

Case Report

Published on 14 Apr 2023

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases

in Cancer Immunity and Immunotherapy

Teng Li
Wuyun Hu
Lan Jin
Xianghua Yin
Dongxu Kang
Longzhen Piao

Frontiers in Oncology

doi 10.3389/fonc.2023.1164368

3,488 views
5 citations

Original Research

Published on 07 Mar 2024

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model

in Cancer Immunity and Immunotherapy

Daniel R. Bergman
Yixuan Wang
Erica Trujillo
Anthony A. Fernald
Lie Li
Alexander T. Pearson
Randy F. Sweis
Trachette L. Jackson

Frontiers in Immunology

doi 10.3389/fimmu.2024.1358019

4,670 views
6 citations

Original Research

Published on 20 Apr 2023

LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer

in Cancer Immunity and Immunotherapy

YiHeng Du
YiZheng Liu
Jin Cao
Xiang Jiang
Yi Wang
Jiang Yu
Bo Wang
XiZhi Wang
BoXin Xue

Frontiers in Immunology

doi 10.3389/fimmu.2023.1113756

4,750 views
9 citations

Articles

Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

A Novel Ferroptosis-Related Prognostic Signature Reveals Macrophage Infiltration and EMT Status in Bladder Cancer

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model

LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer